While high PD-L1 expression suggests that the tumor is in the immune-inflamed phenotype, where ICI would work most effectively, low or no PD-L1 expression indicates that the tumor is in the immune-desert phenotype, which requires chemotherapy, radiotherapy, or an anti-CTL4 inhibitor to activate the priming phase [28]. This evidence concerns the gene SLC44A4 and neoplasm.